Gold bars to be exempt from tariffs, White House clarifies
Radiopharm Theranostics Ltd has announced the acceleration of its RAD204 Phase 1 dose escalation trial according to a recent SEC filing. The Australia-based pharmaceutical company, listed under the name 03 Life Sciences and with a primary focus on pharmaceutical preparations, disclosed this development in a public notice to the Australian Securities Exchange on Monday.
The announcement titled "Acceleration of RAD204 Phase 1 dose escalation trial" signifies a progression in the company’s clinical trials, which could potentially impact the timelines for the drug’s development and availability. The specific details of the acceleration, such as the reasons behind it or the new timeline, were not disclosed in the filing.
This information, contained in a Form 6-K filing, is intended for the month of May 2025 and is filed under the commission file number 001-41621. The document clarifies that the report on Form 6-K, including the exhibit attached, is not to be considered "filed" for purposes of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing under the Securities Act of 1933 unless specifically referenced in such a filing.
The company, with its principal executive office located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia, has indicated that it will continue to file annual reports under the cover of Form 20-F.
The SEC filing was signed by Phillip Hains, the Company Secretary of Radiopharm Theranostics Limited, confirming the authorization and accuracy of the report. The document emphasizes the company’s compliance with the requirements of the Securities Exchange Act of 1934.
Investors and stakeholders are advised to refer to the full SEC filing for a comprehensive understanding of the company’s announcement and its implications. The information in this article is based on the statements provided in the press release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.